Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases

Turbin, Dmitry; Leung, Samuel; Cheang, Maggie C.U.; Kennecke, Hagen; Montgomery, Kelli; McKinney, Steven; Treaba, Diana O.; Boyd, Niki; Goldstein, Lynn C.; Badve, Sunil; Gown, Allen M.; Rijn, Matt van de; Nielsen, Torsten O.; Gilks, C. Blake; Huntsman, David G.

doi:10.1007/s10549-007-9736-z

Cited by 93 publications

(77 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 1 study, carcinomas were scored as 0 (<1% positive), 1 (1% to 25% positive), 2 (>25% to 75% positive), and 3 (>75% positive). 44 The same results were obtained when scored by visual analysis or by image analysis. The proportion of positive cells correlated with the results of the biochemical assay and with prognosis.…”

Section: No Immunoreactive Tumor Cells Presentsupporting

confidence: 64%

Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group

et al. 2015

Self Cite

View full text Add to dashboard Cite

The College does not permit reproduction of any substantial portion of these protocols without its written authorization. The College hereby authorizes use of these protocols by physicians and other health care providers in reporting on surgical specimens, in teaching, and in carrying out medical research for nonprofit purposes. This authorization does not extend to reproduction or other use of any substantial portion of these protocols for commercial purposes without the written consent of the College.The CAP also authorizes physicians and other health care practitioners to make modified versions of the Protocols solely for their individual use in reporting on surgical specimens for individual patients, teaching, and carrying out medical research for non-profit purposes.The CAP further authorizes the following uses by physicians and other health care practitioners, in reporting on surgical specimens for individual patients, in teaching, and in carrying out medical research for non-profit purposes: (1) Dictation from the original or modified protocols for the purposes of creating a text-based patient record on paper, or in a word processing document; (2) Copying from the original or modified protocols into a text-based patient record on paper, or in a word processing document; (3) The use of a computerized system for items (1) and (2), provided that the Protocol data is stored intact as a single text-based document, and is not stored as multiple discrete data fields.Other than uses (1), (2), and (3) above, the CAP does not authorize any use of the Protocols in electronic medical records systems, pathology informatics systems, cancer registry computer systems, computerized databases, mappings between coding works, or any computerized system without a written license from CAP. Applications for such a license should be addressed to the SNOMED Terminology Solutions division of the CAP.Any public dissemination of the original or modified Protocols is prohibited without a written license from the CAP.The College of American Pathologists offers these protocols to assist pathologists in providing clinically useful and relevant information when reporting results of surgical specimen examinations of surgical specimens. The College regards the reporting elements in the "Surgical Pathology Cancer Case Summary" portion of the protocols as essential elements of the pathology report. However, the manner in which these elements are reported is at the discretion of each specific pathologist, taking into account clinician preferences, institutional policies, and individual practice.The College developed these protocols as an educational tool to assist pathologists in the useful reporting of relevant information. It did not issue the protocols for use in litigation, reimbursement, or other contexts. Nevertheless, the College recognizes that the protocols might be used by hospitals, attorneys, payers, and others. Indeed, effective January 1, 2004, the Commission on Cancer of the American College of Surgeons mandated the use of the ...

show abstract

Section: No Immunoreactive Tumor Cells Presentsupporting

confidence: 64%

Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…Several groups have targeted this dilemma by developing automated image analysis techniques with excellent correlations to manual scoring. [6][7][8][9] Our group has previously reported that b-microseminoprotein (MSMB) and the MSMB-binding protein cysteine-rich secretory protein-3 (CRISP3) are independent predictors of patient outcome after radical prostatectomy.…”

mentioning

confidence: 99%

Evaluation of the prognostic significance of MSMB and CRISP3 in prostate cancer using automated image analysis

et al. 2011

View full text Add to dashboard Cite

Despite prostate cancer being the most frequent cancer in men in the Western world, tissue biomarkers for predicting disease recurrence after surgery have not been incorporated into clinical practice. Our group has previously identified b-microseminoprotein (MSMB) and cysteine-rich secretory protein-3 (CRISP3) as independent predictors of biochemical recurrence after radical prostatectomy. The purpose of the present study was to use automated image analysis, enabling quantitative determination of MSMB and CRISP3 expressions in a large cohort and to validate the previous findings. MSMB and CRISP3 protein expressions were assessed on tissue microarrays constructed from 3268 radical prostatectomy specimens. Whole-slide digital images were captured, and a novel cytoplasmic algorithm was used to develop a quantitative scoring model for cytoplasmic staining. Classification regression tree analysis was used to group patients, with different risk for biochemical recurrence, depending on level of protein expression. Patients with tumors expressing high levels of MSMB had a significantly reduced risk for biochemical recurrence after radical prostatectomy (HR ¼ 0.468; 95% CI 0.394-0.556; Po0.001). Multivariate analysis adjusted for clinicopathological parameters revealed that MSMB expression was an independent predictor of decreased risk of recurrence (HR ¼ 0.710; Po0.001). We found no correlation between CRISP3 expression and biochemical recurrence. In this current study, we applied a novel image analysis on a large independent cohort and successfully verified that MSMB is a strong independent factor, predicting favorable outcome after radical prostatectomy for localized prostate cancer.

show abstract

“…The quantitative analysis studies from specialized literature bring relatively few data on the optimisation of the quantitative analysis. A similar optimisation study showed that the automated data generated by the software are not different from those quantified manually by anatomical pathologists [20]. Studies which strictly refer to cut-off placing [21] are insufficient, which makes our study important for the optimisation of the method by generating statistically analysable objective data.…”

Section: Discussionmentioning

confidence: 78%

Optimisation of the quantitative analysis of inflammatory cell infiltrates in breast cancer /Optimizarea analizei cantitative a infiltratului celular inflamator în cancerul mamar

Vrânceanu¹,

Tarniceriu²,

Jitaru³

et al. 2014

Romanian Review of Laboratory Medicine

View full text Add to dashboard Cite

show abstract

Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases

Abstract: Fully automated quantitation of ER immunostaining yields results that do not differ from human scoring against both biochemical assay and patient outcome gold standards.

Cited by 93 publications

References 31 publications

Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group

Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group

Evaluation of the prognostic significance of MSMB and CRISP3 in prostate cancer using automated image analysis

Optimisation of the quantitative analysis of inflammatory cell infiltrates in breast cancer /Optimizarea analizei cantitative a infiltratului celular inflamator în cancerul mamar

Contact Info

Product

Resources

About